Aethlon Medical Advances Oncology Trial, Eyes SLAM Integration with $7M Cash
Aethlon Medical completed cohort one of its Australian oncology trial and began dual-treatment cohort two while testing hemopurifier integration with a smaller SLAM catheter to expand clinical settings. The company reported a $2.06M operating loss, 13.6% higher costs year-over-year and held $7M cash as of December 31.
1. Oncology Trial Progress
Aethlon Medical has completed the first cohort of its Australian oncology trial and initiated the second cohort, where participants receive two hemo purifier treatments per week to assess extended effects on extracellular vesicle levels and T cell responses.
2. SLAM System Integration
The company is advancing compatibility tests for connecting its hemopurifier to the SLAM blood treatment system, which uses a smaller, less invasive catheter to facilitate treatments in oncology or infusion centers rather than dialysis units.
3. Financial Performance
In Q3 2026, consolidated operating expenses rose 13.6% year-over-year due to higher payroll costs, with an operating loss of $2.06 million and reduced interest income of $44,000, partially offset by year-to-date expense reductions and a cash balance of $7 million.
4. Future Outlook and Risks
Aethlon remains in early-stage oncology trials with a third cohort pending, and must navigate potential regulatory approvals and compatibility challenges before broader clinical or commercial deployment of its hemopurifier platform.